• SPX
  • $5,973.10
  • 0.74 %
  • $44.06
  • DJI
  • $43,729.34
  • -0 %
  • -$0.59
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,127.72
  • -0.16 %
  • -$13.02
  • IXIC
  • $19,269.46
  • 1.51 %
  • $285.99
Simulations Plus, Inc. (SLP) Stock Price, News & Analysis

Simulations Plus, Inc. (SLP) Stock Price, News & Analysis

Currency in USD Disclaimer

$30.73

-$0.09

(-0.29%)

Day's range
$30.44
Day's range
$30.99
50-day range
$27.22
Day's range
$36.66
  • Country: US
  • ISIN: US8292141053
52 wk range
$27.22
Day's range
$51.22


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 26.97
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (SLP)
  • Company Simulations Plus, Inc.
  • Price $30.73
  • Changes Percentage (-0.29%)
  • Change -$0.09
  • Day Low $30.44
  • Day High $30.99
  • Year High $51.22

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

  • Last Earnings 07/02/2024
  • Ex-Dividend for 5/16 Dividend 07/29/2024
  • Dividend Payable 08/05/2024
  • Today N/A
  • Next Earnings (Estimated) 01/01/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $56.00
  • High Stock Price Target $65.00
  • Low Stock Price Target $47.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.52
  • Trailing P/E Ratio 88.88
  • Forward P/E Ratio 88.88
  • P/E Growth 88.88
  • Net Income $9.95 M

Income Statement

Quarterly

Annual

Latest News of SLP

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.